title: Improved design of prodromal Alzheimer's disease trials through cohort enrichment and surrogate endpoints.
abstract: Alzheimer's disease (AD) trials initiated during or before the prodrome are costly and lengthy because patients are enrolled long before clinical symptoms are apparent, when disease progression is slow. We hypothesized that design of such trials could be improved by: 1) selecting individuals at moderate near-term risk of progression to AD dementia (the current clinical standard) and 2) by using short-term surrogate endpoints that predict progression to AD dementia. We used a longitudinal cohort of older, initially non-demented, community-dwelling participants (n = 358) to derive selection criteria and surrogate endpoints and tested them in an independent national data set (n = 6,243). To identify a "mid-risk" subgroup, we applied conditional tree-based survival models to Clinical Dementia Rating (CDR) scale scores and common neuropsychological tests. In the validation cohort, a time-to-AD dementia trial applying these mid-risk selection criteria to a pool of all non-demented individuals could achieve equivalent power with 47% fewer participants than enrolling at random from that pool. We evaluated surrogate endpoints measureable over two years of follow-up based on cross-validated concordance between predictions from Cox models and observed time to AD dementia. The best performing surrogate, rate of change in CDR sum-of-boxes, did not reduce the trial duration required for equivalent power using estimates from the validation cohort, but alternative surrogates with better ability to predict time to AD dementia should be able to do so. The approach tested here might improve efficiency of prodromal AD trials using other potential measures and could be generalized to other diseases with long prodromal phases.
authors: MGH BiostatisticsCenter, Massachusetts General Hospital, 50 Staniford St., Boston, MA 02114, USA. emacklin@partners.org
authors: Eric A
authors: EA
authors: Macklin
authors: Deborah
authors: D
authors: Blacker
authors: Bradley T
authors: BT
authors: Hyman
authors: Rebecca A
authors: RA
authors: Betensky
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000523:psychology*; D015415:Biomarkers; D002986:Clinical Trials as Topic; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D009483:Neuropsychological Tests; D017063:Outcome Assessment, Health Care; D062706:Prodromal Symptoms; D012107:Research Design
chemical_list: D015415:Biomarkers
references: J Biopharm Stat. 2010 Nov;20(6):1132-42
references: 21058109
references: Neuropsychology. 2007 Mar;21(2):158-69
references: 17402816
references: JAMA. 1982 May 14;247(18):2543-6
references: 7069920
references: Ann Neurol. 2011 Sep;70(3):418-26
references: 21425187
references: Stat Med. 2011 May 10;30(10):1105-17
references: 21484848
references: Ann Neurol. 2010 Sep;68(3):319-29
references: 20687209
references: Alzheimer Dis Assoc Disord. 2007 Jul-Sep;21(3):249-58
references: 17804958
references: CNS Drugs. 2008;22(11):887-902
references: 18840031
references: Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4):210-6
references: 17132964
references: J Int Neuropsychol Soc. 2001 Jul;7(5):631-9
references: 11459114
references: Alzheimers Dement. 2011 Nov;7(6):602-610.e2
references: 21745761
references: Ann Intern Med. 1996 Oct 1;125(7):605-13
references: 8815760
references: Neurology. 1993 Nov;43(11):2412-4
references: 8232972
references: J Nutr Health Aging. 2010 Apr;14(4):295-8
references: 20305999
references: J Psychiatr Res. 1975 Nov;12(3):189-98
references: 1202204
references: Arch Neurol. 2007 Jun;64(6):862-71
references: 17562935
references: Nat Med. 2010 Nov;16(11):1218-22
references: 21052077
references: Arch Neurol. 2000 May;57(5):675-80
references: 10815133
references: Alzheimers Dement. 2011 May;7(3):257-62
references: 21514247
references: Biometrics. 2012 Mar;68(1):258-67
references: 21838811
references: Biometrics. 1988 Mar;44(1):229-41
references: 3358991
references: BMC Bioinformatics. 2008 Jul 11;9:307
references: 18620558
references: Br J Psychiatry. 1982 Jun;140:566-72
references: 7104545
references: Lancet. 2006 Jul 29;368(9533):387-403
references: 16876668
references: Neurology. 1984 Jul;34(7):939-44
references: 6610841
references: Lancet Neurol. 2010 Jan;9(1):119-28
references: 20083042
references: Pharmacogenomics. 2010 Dec;11(12):1679-82
references: 21142910
references: Lancet. 2008 Jul 19;372(9634):216-23
references: 18640458
references: J Neural Transm (Vienna). 2011 Sep;118(9):1361-78
references: 21647682
references: Can J Neurol Sci. 2007 Mar;34 Suppl 1:S84-9
references: 17469689
references: Arch Gen Psychiatry. 2007 Dec;64(12):1443-50
references: 18056553